The plaintiffs trade secret misappropriation claims arise out of Coronary Artery Bypass Graft (CABG) clinical drug trials for Bextra, a second generation COX-2 inhibitor.
According to plaintiff non-profit Ischemia Research & Education Foundation (IREF), a proposed contract provided that Pfizer could have productive access to IREF's EPI1 and EPI2 adverse events databases for a CABG drug trial. However, Pfizer never signed the contract. Instead, the plaintiff said, Pfizer hired an IREF employee, who provided parts of the databases for Pfizer's use.
IREF sought $55M in direct damages.
Pfizer denied that it had conspired with the IREF employee, or stole any trade secret, but suggested that the employee had his own dispute with IREF, and might have acted based upon that dispute.
The jury awarded IREF damages of over $38M for misappropriation of trade secrets.
Damages: 38,700,000
Description | Attorney | Witness | Presence | |||
---|---|---|---|---|---|---|
00:00:00 | General Case Activities | |||||
00:18:25 | Opening Statement | Marino, Daniel | ||||
01:12:31 | End of Session |
Recording Disclaimer: This proceeding was recorded in full except noted sections that were not recorded.